vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $9.2M, roughly 1.2× Foghorn Therapeutics Inc.). On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 11.9%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 3.5%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
FHTX vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $11.5M |
| Net Profit | $-21.7M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -258.2% | -10.1% |
| Net Margin | -234.3% | — |
| Revenue YoY | 223.8% | 11.9% |
| Net Profit YoY | -11.1% | — |
| EPS (diluted) | $-0.35 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $11.5M | ||
| Q3 25 | $8.2M | $13.2M | ||
| Q2 25 | $7.6M | $13.8M | ||
| Q1 25 | $6.0M | $13.1M | ||
| Q4 24 | $2.9M | $10.2M | ||
| Q3 24 | $7.8M | $10.9M | ||
| Q2 24 | $6.9M | $11.6M | ||
| Q1 24 | $5.0M | $10.7M |
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-15.8M | $15.0K | ||
| Q2 25 | $-17.9M | $-143.0K | ||
| Q1 25 | $-18.8M | $19.0K | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | $-19.1M | $-551.0K | ||
| Q2 24 | $-23.0M | $-319.0K | ||
| Q1 24 | $-25.0M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -258.2% | -10.1% | ||
| Q3 25 | -226.9% | 0.1% | ||
| Q2 25 | -279.2% | -1.9% | ||
| Q1 25 | -385.0% | -0.1% | ||
| Q4 24 | -840.5% | -10.3% | ||
| Q3 24 | -305.5% | -7.7% | ||
| Q2 24 | -386.6% | -3.8% | ||
| Q1 24 | -558.3% | -12.2% |
| Q4 25 | -234.3% | — | ||
| Q3 25 | -194.4% | 0.1% | ||
| Q2 25 | -237.3% | -1.0% | ||
| Q1 25 | -316.4% | 0.1% | ||
| Q4 24 | -682.9% | — | ||
| Q3 24 | -244.9% | -5.1% | ||
| Q2 24 | -333.6% | -2.8% | ||
| Q1 24 | -495.4% | -9.7% |
| Q4 25 | $-0.35 | $-0.11 | ||
| Q3 25 | $-0.25 | $0.00 | ||
| Q2 25 | $-0.28 | $-0.01 | ||
| Q1 25 | $-0.30 | $0.00 | ||
| Q4 24 | $-0.23 | $-0.80 | ||
| Q3 24 | $-0.31 | $-0.06 | ||
| Q2 24 | $-0.45 | $-0.03 | ||
| Q1 24 | $-0.59 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $31.1M |
| Total Assets | $198.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $20.4M | ||
| Q3 25 | $89.3M | $20.0M | ||
| Q2 25 | $72.6M | $17.7M | ||
| Q1 25 | $61.0M | $14.2M | ||
| Q4 24 | $55.5M | $14.4M | ||
| Q3 24 | $57.7M | $11.3M | ||
| Q2 24 | $138.9M | $11.1M | ||
| Q1 24 | $79.3M | $10.6M |
| Q4 25 | $-108.5M | $31.1M | ||
| Q3 25 | $-89.7M | $31.8M | ||
| Q2 25 | $-76.7M | $31.3M | ||
| Q1 25 | $-61.7M | $30.9M | ||
| Q4 24 | $-45.5M | $30.6M | ||
| Q3 24 | $-28.3M | $38.4M | ||
| Q2 24 | $-14.3M | $38.5M | ||
| Q1 24 | $-97.5M | $38.6M |
| Q4 25 | $198.1M | $44.8M | ||
| Q3 25 | $205.0M | $45.0M | ||
| Q2 25 | $226.2M | $44.5M | ||
| Q1 25 | $258.7M | $44.2M | ||
| Q4 24 | $284.0M | $44.0M | ||
| Q3 24 | $308.4M | $50.5M | ||
| Q2 24 | $328.6M | $50.4M | ||
| Q1 24 | $255.0M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $609.0K | ||
| Q3 25 | $-18.9M | $3.6M | ||
| Q2 25 | $-21.0M | $3.6M | ||
| Q1 25 | $-24.0M | $-161.0K | ||
| Q4 24 | $-24.5M | $2.4M | ||
| Q3 24 | $-21.0M | $327.0K | ||
| Q2 24 | $-25.5M | $636.0K | ||
| Q1 24 | $-29.3M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-21.0M | $3.6M | ||
| Q1 25 | $-24.0M | $-171.0K | ||
| Q4 24 | $-25.0M | $2.4M | ||
| Q3 24 | $-21.3M | $259.0K | ||
| Q2 24 | $-25.6M | $499.0K | ||
| Q1 24 | $-29.4M | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -278.2% | 25.9% | ||
| Q1 25 | -403.2% | -1.3% | ||
| Q4 24 | -875.3% | 23.2% | ||
| Q3 24 | -273.0% | 2.4% | ||
| Q2 24 | -371.0% | 4.3% | ||
| Q1 24 | -583.1% | -14.9% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 16.8% | 0.1% | ||
| Q3 24 | 4.0% | 0.6% | ||
| Q2 24 | 0.2% | 1.2% | ||
| Q1 24 | 2.0% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
